AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
Company News
AbbVie Inc. $ABBV Position Reduced by Cliftonlarsonallen Wealth Advisors LLC
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
A Look at AbbVie Inc (ABBV) After 2.4% Decline -- GF Value $222.10 vs Price $274.36
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income
Netflix, DocuSign And A Health Care Stock On CNBC's ‘Final Trades'
AbbVie (NYSE:ABBV) Reaches New 52-Week High – Here’s Why
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
Prediction: AbbVie's Next Billion-Dollar Opportunity Is Taking Shape
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens